Search DIAN Data Resource Requests

Title:Small Vessel Disease and Vascular Risk Factors in Dominantly Inherited Alzheimer’s Disease

Date of Request:08/03/2021

Status:Pending Approval

ID:DIAN-D2113

Aim 1:To examine small vessel disease features, vascular risk factors and angiogenesis in dominantly inherited Alzheimer’s disease

Title:Network level analysis of progressive brain degeneration in autosomal dominant Alzheimer disease

Date of Request:07/23/2021

Status:Approved

ID:DIAN-D2112

Aim 1:1. Characterize the spatio-temporal progression of structural and functional brain network degeneration in AD based on estimated year of symptom onset

Aim 2:2. Determine the relationship between neuronal injury markers based on blood (e.g., NfL), cerebrospinal fluid (e.g., AB42), and PET (e.g., tau) with MRI markers of brain network dysfunction and clinical symptoms of cognitive decline cross-sectionally and longitudinally.

Title:Relationship between regional baseline and longitudinal tau PET SUVR, and correlations with change in cognition in participants from the DIAN-TU study

Date of Request:07/19/2021

Status:Approved

ID:DIAN-D2111

Aim 1:Characterize the spatial patterns of tau deposition at baseline and over time in the DIAD population

Aim 2:Estimate the rate of change in tau deposition in DIAD participants in each of the provided parcellated brain regions

Aim 3:Identify the (meta)ROI(s) at baseline that best correlate with change in tau PET SUVR and change in cognition, respectively, over time

Aim 4Characterize the relationship between change in tau PET SUVR and change in cognition (and other biomarkers)

Title:Gene Therapy for ADAD patients harboring PS1 mutations

Date of Request:07/13/2021

Status:Pending Approval

ID:DIAN-D2109

Aim 1:Develop AAV9 vectors expressing hPSEN1 (completed)

Aim 2:Evaluate AAV-PSEN1 vectors in transfected HEK293 cells and PS1 mutant iPSC lines (ongoing)

Aim 3:Evaluate AAV-PSEN1 vectors in PS1 mutant knock-in mice for rescue of biochemical and neuropathological phenotypes (ongoing)

Aim 4Evaluate AAV-PSEN1 vectors in nonhuman primates for expression and biodistribution in brain

Title:Alzheimer's Research Using Gene Expression Analysis Data

Date of Request:07/09/2021

ID:DIAN-D2110

Aim 1:Evaluating transcriptional profile of activated microglia from brains of individuals with Alzheimer's Disease (AD)

Aim 2:Comparing transcriptional profile from individuals with AD to transcriptional profiles of non AD controls

Aim 3:Comparing gene expression differences in AD cases and controls to the results of GWAS

Title:Association of b-amyloid accumulation and cognitive decline in healthy older adults : a systematic review and meta-analysis

Date of Request:05/27/2021

ID:DIAN-D2108

Aim 1:Systematic review and meta-analysis of selected articles studying the longitudinal association between amyloid accumulation and cognitive decline in preclinical Alzheimer's disease (in cognitively healthy older adults)

Aim 2:Obtain data from the following article : Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer’s disease

Title:Characterization of the Neuroinflammation in Autosomal Dominant Alzheimer Disease Using Neuro-Inflammation Imaging

Date of Request:04/26/2021

ID:DIAN-D2107

Aim 1:Determine the trajectory of NII neuroinflammation biomarkers during the natural course of AD in the DIAN cohort.

Aim 2:Examine the association between whole-brain NII neuroinflammation biomarkers and CSF inflammation measures (sTREM2 and YKL40) in the DIAN cohort.

Aim 3:Assess the relationships among neuroinflammation measured by NII, amyloid deposition, and tauopathy measured by PET tracers in the DIAN cohort.

Title:Plasma biomarkers in Autosomal Dominant AD

Date of Request:03/31/2021

Status:Approved

ID:DIAN-D2106

Aim 1:Aim 1a: Determine whether plasma markers of amyloid (i.e., Ab42, Ab42/40) at baseline predict current and future CSF and PET markers of amyloid. Aim 1b: Assess longitudinal changes in plasma amyloid in relation to changes in CSF and PET amyloid.

Aim 2:Aim 2a: Determine whether plasma markers of tau (i.e., t-tau, p-tau181) at baseline predict current and future CSF and PET markers of tau. Aim 2b: Assess longitudinal changes in plasma tau in relation to changes in CSF and PET tau.

Aim 3:Aim 3a: Determine if the combination of plasma amyloid and tau markers at baseline predict current and future downstream markers (i.e., neurodegeneration [MRI], cognitive performance, and clinical status [clinical dementia rating (CDR) sum of boxes] in ADAD. Aim 3b: Assess longitudinal changes in plasma amyloid and tau in relation to changes in downstream markers of neurodegeneration and cognitive status.

Title:Using quantitative traits to identify new genes, biomarkers and drug targets for ADAD and LOAD

Date of Request:09/08/2020

Status:approved

ID:DIAN-D2018

Aim 1:To identify genetic variants associated with biomarker levels and quantitative traits in ADAD

Aim 2:To identify novel variants and genes associated with onset and progression by using multi-omics QTL data

Aim 3:To identify novel molecular biomarkers and drug targets by combining multi-omic QTL and Mendelian randomization analysis

Title:Imaging White matter hyperintensities and Tau in Autosomal Dominant Alzheimer’s Disease

Date of Request:09/04/2020

ID:DIAN-D2017

Aim 1:To determine the difference in the relationship among tau and WMH, independent or dependent on amyloid, between mutation carriers and controls.

Aim 2:To characterize the timing of the relationship among tau and WMH in mutation carriers compared to controls.

Aim 3:To characterize any added benefit to incorporating spatial information from tau PET in Aims 1 and 2.

Aim 4To determine the difference in the relationship among baseline WMH and tau accumulation between mutation carriers and controls.